US 12,269,883 B2
Binding agents and methods of using the same
Courtney Crane, Seattle, WA (US); Kristine Swiderek, Seattle, WA (US); and Susan Julien, Seattle, WA (US)
Assigned to Mozart Therapeutics, Inc, Seattle, WA (US)
Filed by MOZART THERAPEUTICS, INC., Seattle, WA (US)
Filed on Oct. 4, 2024, as Appl. No. 18/907,087.
Application 18/907,087 is a continuation of application No. 18/264,056, previously published as PCT/US2022/014881, filed on Feb. 2, 2022.
Claims priority of provisional application 63/298,028, filed on Jan. 10, 2022.
Claims priority of provisional application 63/209,949, filed on Jun. 11, 2021.
Claims priority of provisional application 63/161,325, filed on Mar. 15, 2021.
Claims priority of provisional application 63/148,016, filed on Feb. 10, 2021.
Claims priority of provisional application 63/145,394, filed on Feb. 3, 2021.
Prior Publication US 2025/0026830 A1, Jan. 23, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)
CPC C07K 16/2815 (2013.01) [A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 8 Claims
 
1. A binding agent comprising:
a first binding domain that specifically binds to CD8 or a subunit of CD8 and comprises a heavy chain variable region (VH) comprising an hCDR1, an hCDR2, and an hCDR3 and a light chain variable region (VL) comprising an lCDR1, an lCDR2, and an lCDR3, wherein the hCDR1, hCDR2, hCDR3, lCDR1, lCDR2, and lCDR3 have amino acid sequences of SEQ ID NO: 83 to SEQ ID NO:88, respectively;
a second binding domain that specifically binds to an inhibitory killer-cell immunoglobulin-like receptor (KIR) protein expressed on CD8+KIR+ T regulatory cells (Tregs), wherein the second binding domain comprises a VH comprising an hCDR1, an hCDR2, and an hCDR3 and a VL comprising an lCDR1, an lCDR2, and an lCDR3, wherein the hCDR1, hCDR2, hCDR3, lCDR1, lCDR2, and lCDR3 have amino acid sequences of SEQ ID NO: 103 to SEQ ID NO:108, respectively; and
an IgG Fc domain.